CHMP recommends licence extension for budesonide (Jorveza)

The CHMP have recommended market authorisation of a maintenance use of budesonide for eosinophilic oesophagitis. It is currently licenced for a 6-12 week course of treatment only. Maintenance dose is 0.5 – 1mg twice daily depending on clinical requirement.

European Medicines Agency